The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth ...

Roche has waved goodbye to a inflammation drug from Kiniksa Pharmaceuticals—as well as the $100 million that the pharma paid for the therapy—as part of a ...

By Maggie Fick and Michael Erman SAN FRANCISCO, Jan 26 (Reuters) - Artificial intelligence has yet to deliver on the most ...

BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced ...

The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence ...

Roche is expanding its scope to a promising but competitive new obesity target, committing $1.65 billion up front to partner on a clinical-stage Zealand Pharma molecule with the potential to be a ...

AI in drug discovery offers key market opportunities by enhancing drug development efficiency, reducing costs, and improving success rates. It supports personalized medicine, facilitating custom ...

Roche remains a Buy, driven by strong pipeline progress and conservative valuation, with shares up 36% since my last recommendation. Learn more about RHHBY stock here.